Skip to main content

Table 3 Characteristics of patients responding and not responding to nivolumab treatment according to iPERCIST

From: Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST

  iPERCIST responders (n = 19) iPERCIST non-responders (n = 9) p value
Male (%) 13 (68) 4 (44) 0.6775
Tobacco use (%) 16 (84) 7 (78) 0.99
Age (mean, range), years 64 (42–79) 58 (50–79) 0.22
Adenocarcinoma (%) 14 (74) 7 (78) 0.99
Lines of chemotherapy before nivolumab (mean, range) 1.8 (1–5) 2.0 (1–5) 0.35
Survival (months, median) 19.9 3.6 < 0.0001